A major challenge facing the pharmaceutical industry and drug development today is that a large number (40 to 70%) of active pharmaceutical ingredients (API) have low water solubility which lead to poor bioavailability and often therapeutic failure. These hydrophobic molecules fall under the category of Biopharmaceutics Classification System (or BCS) class II and IV drugs. We have developed a nanotechnology approach (referred to as (n-Fast) to enhance bio-absorbability and efficacy by enhancing the water solubility – the equivalent of fast dissolving version of the drug. We have already worked with several API that was reported previously